OPSONA Therapeutics Ltd, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James' Hospital, Dublin 8, Ireland.
Arthritis Res Ther. 2009;11(5):243. doi: 10.1186/ar2729. Epub 2009 Oct 14.
The past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.
过去十年见证了能够驱动感染和组织损伤中促炎细胞因子产生的受体家族的描述。在炎症性关节疾病的背景下,已经研究了两大类-- Toll 样受体 (TLR) 和 NOD 样受体 (NLR)。TLR 如 TLR2 和 TLR4 被认为与类风湿关节炎、强直性脊柱炎、莱姆关节炎和骨关节炎的病理学有关。NALP3 已被确定为产生 IL-1β的关键 NLR,并已显示在痛风中具有特殊作用。这些发现提出了新的治疗机会,可能允许用小分子抑制剂替代生物制剂。